Anti-PD-1, anti-PD-L1, and anti-CTLA-4 therapies have reported ICI-DM incidences of 1.18%, 0.73%, and 0.33%, respectively; a higher rate of up to 2.60% is reported for anti–CTLA-4/anti–PD-1/anti–PD-L1 combination therapy [1]. Here, CTLA4 is linked to diabetes mellitus.